<DOC>
	<DOCNO>NCT00716911</DOCNO>
	<brief_summary>RATIONALE : Tests measure certain change blood patient high risk cytomegalovirus infection may help doctor learn predict cytomegalovirus infection donor stem cell transplant . PURPOSE : This clinical trial study test measure change blood patient high risk cytomegalovirus infection undergo donor bone marrow transplant peripheral stem cell transplant .</brief_summary>
	<brief_title>Measuring Changes Blood Patients High Risk Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant Peripheral Blood Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : - To document quantitative characteristic cytomegalovirus ( CMV ) -specific HLA-peptide tetramer-binding assay ( TBA ) cytotoxic T lymphocytes ( CTLs ) patient undergone allogeneic bone marrow transplantation ( BMT ) peripheral blood stem cell transplantation ( PBSCT ) . - To confirm optimal TBA condition CTL characterization patient . - To compare TBA result patient conventional assay CTL function . - To compare CMV-specific TBA first 3 month allogeneic BMT PBSCT determine whether bind function , either donor recipient , surrogate marker protection risk CMV infection patient . - To determine whether acquisition CMV-specific TBA protect risk CMV disease patient active CMV infection allogeneic BMT PBSCT . OUTLINE : This multicenter study . Patients accrue initially cohort 1 sufficient number stem cell transplantation ( SCT ) recipient enrol . Patients accrue cohort 2 base document cytomegalovirus ( CMV ) infection preemptive treatment ganciclovir within 90 day SCT ( patient previously accrue cohort 1 accrue cohort 2 develop CMV infection ) . - Cohort 1 : Patients undergo blood sample collection approximately day 40 , 90 , 120 , 150 , 180 , 360 post transplantation . Samples analyze ( determine development CMV immunity ) prevalence CMV-specific cytotoxic T-lymphocytes ( CTL ) HLA-peptide tetramer-binding assay ( TBA ) pp65 , without vitro stimulation ( IVS ) . Samples collect day 40 90 also analyzed chromium release assay ( CRA ) . Patients suspect develop CMV viremia may receive ganciclovir accord standard clinical practice . - Cohort 2 : Patients undergo blood sample collection approximately day 90 , 120 , 150 , 180 , 360 SCT . Samples analyze TBApp65 stain prospective measurement CMV-specific CTL function . All patient undergo routine clinical surveillance CMV infection day 21 100 SCT . CMV viral load measurement obtain twice weekly CMV-DNA PCR assay blood cell plasma shell-vial blood culture . In cohort 2 , CMV viral load also determine day 90 ( previously part cohort 1 ) , 120 , 150 , 180 , 360 . The CMV infection data obtain compare TBA CTL measurement use HLA-specific tetramers IVS-induced cytotoxicity assay . Clinical event , graft-versus-host disease , underlie disease status , procedure-related complication also analyze correlate TBA result . Stromal cell culture obtain marrow donor time marrow harvest use target cell CTL assay . Donor saliva sample also obtain detection CMV infection shell-vial method .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion City Hope National Medical Center : Patient undergone matchedrelated matchedunrelated allogeneic bone marrow peripheral blood stem cell transplantation ( SCT ) hematological malignancy ( e.g. , aplastic anemia myelodysplastic syndrome ) At risk cytomegalovirus ( CMV ) infection disease due 1 follow risk factor : CMVseropositive prior transplantation Received SCT CMVseropositive donor Donor matchedrelated SCT Healthy volunteer evaluate concurrently SCT recipient establish normal value CMVseronegative CMVseropositive person Any HLA serotypes allow PATIENT CHARACTERISTICS : See Disease Characteristics PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>cytomegalovirus infection</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL negative</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>stage I multiple myeloma</keyword>
</DOC>